Mental health respite facilities are filling care gaps in over a dozen states

Plus, news about Pyx­is, Epi­to­pea and Genevant: Idor­sia’s deal for blood pres­sure drug hits snag: The Swiss com­pa­ny Sign up to read this article for

Jazz Phar­ma­ceu­ti­cals said Thurs­day that the high­est dose of su­ve­cal­tamide failed a Phase 2b tri­al in es­sen­tial tremor, a neu­ro­log­i­cal con­di­tion that caus­es in­vol­un­tary shak­ing

Yet again, there’s a new COVID variant on the scene, but experts say there’s no cause for concern. For the 2-week period ending October 14,